10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

LRCH4 antibody - middle region

Rabbit Polyclonal Antibody
Catalog # AI12562

Product Information

Application	WB
Primary Accession	O75427
Other Accession	NM_002319, NP_002310
Reactivity	Human, Mouse, Rat, Rabbit, Zebrafish, Pig, Dog, Guinea Pig, Horse, Bovine
Predicted	Human, Mouse, Rat, Rabbit, Pig, Dog, Guinea Pig, Horse, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	73450

Additional Information

Gene ID	4034
Alias Symbol	FLJ40101, FLJ46315, LRN, LRRN1, LRRN4, PP14183, SAP25
Other Names	Leucine-rich repeat and calponin homology domain-containing protein 4, Leucine-rich repeat neuronal protein 4, Leucine-rich neuronal protein, LRCH4, LRN, LRRN1, LRRN4
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-LRCH4 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	LRCH4 antibody - middle region is for research use only and not for use in diagnostic or therapeutic procedures.


Protein Information

Name	LRCH4 (HGNC:6691)
Synonyms	LRN, LRRN1, LRRN4
Function	Accessory protein that regulates signaling by multiple TLRs, acting as a broad-spanning regulator of the innate immune response. In macrophages, binds LPS and promotes proper docking of LPS in lipid raft membrane. May be required for lipid raft maintenance.
Cellular Location	Cell membrane {ECO:0000250|UniProtKB:Q921G6}; Single-pass membrane protein

References

Olsen,J.V.,(2006)Cell127(3),635-648ReconstitutionandStorage:Forshorttermuse,storeat2-8Cupto1week.Forlongtermstorage,storeat-20Cinsmallaliquotstopreventfreeze-thawcycles.

Images



WB Suggested Anti-LRCH4 Antibody Titration: 0.2-1 µg/ml
ELISA Titer: 1:62500
Positive Control: Hela cell lysate

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.